{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:37:25Z","timestamp":1762324645691,"version":"3.37.3"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To reach a consensus on the instruments to be used in clinical practice to evaluate the effectiveness of biological disease-modifying antirheumatic drug (bDMARD) treatment in patients with psoriatic arthritis (PsA) in the short to medium term (3\u20136 mos), and to establish the minimum health outcomes for treatment continuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A 2-round Delphi questionnaire was developed based on both the information gathered in the literature review and 4 discussion groups. The suitability and feasibility of the proposed sets of instruments were assessed on a 7-point Likert scale. Consensus was established when at least 75% of healthcare professionals (HCP) reached agreement. To define a minimum health outcome to continue treatment, a combination of 4 disease activity states and 3 health-related quality of life states were defined for 3 hypothetical patient profiles. HCP were given a dichotomous choice (yes\/no) to respond to whether they would continue treatment in each case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The second round was completed by 106 HCP. Consensus was reached on the use of (1) Disease Activity in Psoriatic Arthritis + Psoriatic Arthritis Impact of Disease (PsAID12) or minimal disease activity + PsAID12 + C-reactive protein, in peripheral PsA; and (2) Ankylosing Spondylitis Disease Activity Score + PsAID12, in axial PsA. Health outcomes considered sufficient to continue treatment were stricter for bDMARD-naive patients than for patients who failed several bDMARD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>To the best of our knowledge, this is the first multidisciplinary consensus on a set of outcomes for the evaluation of bDMARD effectiveness in PsA, in routine clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.191056","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T17:25:13Z","timestamp":1580577913000},"page":"1637-1643","source":"Crossref","is-referenced-by-count":14,"title":["Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-0573","authenticated-orcid":false,"given":"Juan D.","family":"Ca\u00f1ete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-6767","authenticated-orcid":false,"given":"Joan M.","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Ruben","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-266X","authenticated-orcid":false,"given":"Miguel J.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-2196","authenticated-orcid":false,"given":"Miguel","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-2454","authenticated-orcid":false,"given":"Luis","family":"Liz\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"key":"2022062017051001000_47.11.1637.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.210"},{"key":"2022062017051001000_47.11.1637.2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14737167.2015.965154","article-title":"The indirect costs of psoriatic arthritis: systematic review and meta-analysis","volume":"15","author":"Kawalec","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Suppl 10","key":"2022062017051001000_47.11.1637.3","first-page":"S235","article-title":"The predictors of reduced work productivity in patients with psoriatic arthritis","volume":"64","author":"Papneja","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022062017051001000_47.11.1637.4","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation Survey Data 2003\u20132011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"key":"2022062017051001000_47.11.1637.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu264"},{"key":"2022062017051001000_47.11.1637.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22404"},{"key":"2022062017051001000_47.11.1637.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2022062017051001000_47.11.1637.8","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354"},{"key":"2022062017051001000_47.11.1637.9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-017-3908-y","article-title":"Current concepts and unmet needs in psoriatic arthritis","volume":"37","author":"Mahmood","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022062017051001000_47.11.1637.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2022062017051001000_47.11.1637.11","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1362"},{"key":"2022062017051001000_47.11.1637.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.12.1167"},{"key":"2022062017051001000_47.11.1637.13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022062017051001000_47.11.1637.14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.semarthrit.2017.09.002","article-title":"A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative","volume":"47","author":"H\u00f8jgaard","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2022062017051001000_47.11.1637.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21552"},{"key":"2022062017051001000_47.11.1637.16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000217"},{"key":"2022062017051001000_47.11.1637.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"2022062017051001000_47.11.1637.18","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1016\/j.arthro.2018.10.004","article-title":"Research pearls: expert consensus based evidence using the Delphi method","volume":"34","author":"Hohmann","year":"2018","journal-title":"Arthroscopy"},{"key":"2022062017051001000_47.11.1637.19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-37"},{"key":"2022062017051001000_47.11.1637.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209511"},{"key":"2022062017051001000_47.11.1637.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2022062017051001000_47.11.1637.22","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-20-01-028"},{"key":"2022062017051001000_47.11.1637.23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2022062017051001000_47.11.1637.24","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0618-5"},{"key":"2022062017051001000_47.11.1637.25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.reuma.2017.08.007","article-title":"Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis","volume":"14","author":"Torre Alonso","year":"2018","journal-title":"Reumatol Clin"},{"key":"2022062017051001000_47.11.1637.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2022062017051001000_47.11.1637.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2022062017051001000_47.11.1637.28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/839425","article-title":"Measuring disease activity in psoriatic arthritis","volume":"2012","author":"Wong","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2022062017051001000_47.11.1637.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2022062017051001000_47.11.1637.30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-017-1277-1","article-title":"Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study","volume":"19","author":"Queiro","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022062017051001000_47.11.1637.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171094"},{"key":"2022062017051001000_47.11.1637.32","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2734-8"},{"key":"2022062017051001000_47.11.1637.33","first-page":"23","article-title":"Validation of the composite index DAPSA (Disease Activity for Psoriatic Arthritis) in a cohort of patients with psoriasis arthritis in Argentina and determination of their cut-off values","volume":"37","author":"Gallino Yanzi","year":"2016","journal-title":"Rev Argent Reum"},{"key":"2022062017051001000_47.11.1637.34","doi-asserted-by":"publisher","DOI":"10.4137\/hsi.s11093"},{"key":"2022062017051001000_47.11.1637.35","unstructured":"US Food and Drug Administration . Patient-reported outcome measures: use in medical product development to support labeling claims. [Internet. Accessed July 2, 2020.] Available from: www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"key":"2022062017051001000_47.11.1637.36","unstructured":"European Medicines Agency (EMA) . Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMEA\/CHMP 2005. [Internet. Accessed July 2, 2020.] Available from: www.ema.europa.eu\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf"},{"key":"2022062017051001000_47.11.1637.37","first-page":"73","article-title":"Treatment of psoriatic arthritis: management recommendations","volume":"33","author":"Gossec","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022062017051001000_47.11.1637.38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160924"},{"key":"2022062017051001000_47.11.1637.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211996"},{"key":"2022062017051001000_47.11.1637.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2022062017051001000_47.11.1637.41","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2022062017051001000_47.11.1637.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211998"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.191056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:08:49Z","timestamp":1655770129000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.191056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.3899\/jrheum.191056"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.191056","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}